Attorney Docket No.: PR60689USw

REMARKS

Status of the Claims

Following entry of the above amendment, claims 1, 8, 9, 12, 14, 18, and 20 will be pending. Claims 2-7, 10, 11, 13, 15-17, 26, and 27 have been cancelled. Claims 26 and 27 are cancelled due to the restriction requirement. Claims 1, 9, and 18 have been amended to further define certain substituents of the compounds of Formula (I). Support for the amendments can be found in the original claims and specification including, for example, original claims 2 and 3. No new matter has been added by way of amendment.

The Restriction Requirement

The Examiner states that the present claims lack unity of invention and has required the election of a single group of claims selected from:

Group I: Claims 1-18 and 20

Group II: Claims 26 and 27

Applicants elect to prosecute the claims of Group I (claims 1-18 and 20). Applicants expressly reserve the right to file divisional applications on the non-elected subject matter.

The Examiner has further required the election of a single species for examination, to which the claims will be restricted if now generic claim is finally held to be allowable. Applicants elect to prosecute N^2 -[4-cyano-3-(trifluoromethyl)phenyl]- N^2 - (cyclopropylmethyl)glycinamide. Claims 1, 8, 9, 12, 14, 18, and 20 read on the elected species.

Applicants believe the present claims are in condition for allowance and such action is respectfully requested. Applicants believe that no other fees are due in connection with the filing of this paper other than those specifically authorized herewith.

Should any other fees be deemed necessary to effect the timely filing of this paper, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392. If the Examiner has any outstanding issues with the pending claims, he is encouraged to telephone the undersigned at (919) 483-1467 for expeditious handling.

Attorney Docket No.: PR60689USw

Respectfully submitted,

Kathryn L. Coulter

Attorney for Applicant Registration No. 45,889

Corporate Intellectual Property

Date: 8/27/08 Customer No. 23347

GlaxoSmithKline